AXIM Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 17, 2022 at 02:23 am IST
Share
AXIM Biotechnologies, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 1.22 million compared to USD 3.83 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.03 a year ago. Basic loss per share was USD 0.01 compared to USD 0.03 a year ago. Diluted loss per share was USD 0.01 compared to USD 0.03 a year ago.
For the six months, net loss was USD 3.31 million compared to USD 4.69 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.04 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.04 a year ago. Basic loss per share was USD 0.01 compared to USD 0.04 a year ago. Diluted loss per share was USD 0.01 compared to USD 0.04 a year ago.
Axim Biotechnologies, Inc. is a vertically integrated research and development company. The Company is focused on improving the landscape for the diagnosis of ophthalmological conditions such as dry eye disease (DED) through rapid diagnostic tests. Its core competencies include development of rapid lateral flow immunoassays, reagents, and monoclonal antibody development for such assays. Its product categories include Eye Health, wherein the Company acquired two FDA cleared tests for dye eye disease and has internally developed a third assay; and SARS-CoV-2 neutralizing antibody tests. The Company is focused on developing a proprietary diagnostic platform that can be adapted to test for a variety of analytes including SARS-Cov-2, Lactoferrin, IgE, Lacritin, and MMP-9. Its platform capability can also be applied to rapid testing for vaccine candidates. Its platform can also be used to enable point-of-care detection for one or more cancers using a unique cancer biomarker, QSOX1-L.